Marek Health Reviews: Deep Labs, No Drug Prices

The one-sentence version

Marek Health sells the deepest diagnostics in this category and prices them properly — a panel menu from $150 to $1,950, with the biomarker count beside each one. What it does not price is the treatment. A $299 intake plus a required lab panel of at least $450 gets you to a plan; the medication that plan recommends is described in Marek's own catalogue only as "separate and varies by dose." It grades B, 8 points out of 14 as the board currently stands, and the deduction is entirely that missing figure. The grade is computed from published terms alone and cannot see who pays us.

What it is, and who it's for

Marek Health is a telehealth-only practice — "any physical locations exist solely for administrative purposes and are not open to the public" — built around a program it trademarks as Guided Optimization, run by Marek Health LLC of Pontiac, Michigan through five named medical groups. Its formulary is unusually large: "500+ therapies, including testosterone replacement therapy (TRT), GLP-1 receptor agonists (semaglutide, tirzepatide), peptides, thyroid support, and more." Twelve peptides are named, including sermorelin, tesamorelin, CJC-1295 with ipamorelin and BPC-157; a separate longevity category carries NAD+, rapamycin, GlyNAC and injectable glutathione.

The buyer this suits wants data first: someone who would rather spend $595 on a hundred-marker panel and a coach's read than $199 on a vial. The buyer it does not suit wants the all-in monthly cost before starting. See longevity biomarker panels.

One note on sourcing: Marek's site serves an empty document to automated readers, so every figure and quote below comes from a page Marek publishes itself, and where it publishes no number we say so rather than guess.

What it actually costs

All figures verified against Marek-published pages on 26 July 2026.

The intake and the lab minimum. "Your intake assessment is a one-time cost of $299. No subscriptions and no hidden fees." Marek states the fee is credited toward your first provider visit, and that it "requires a minimum $450 lab panel purchase for the initial assessment", with most clients investing "$450–$800 in their initial panel."

The panel menu, which is genuinely excellent. Marek's own store publishes a complete price list with the marker count beside each panel: Essential at $150, a Base Lab Panel at $250 (65 markers), Total Health — Comprehensive at $495 (80+), a pre-TRT Testosterone Panel at $595, Total Health — Complete at $895 (100+) and an Executive panel at $1,950 (130+). Testosterone runs by LC/MS rather than the "cheaper immunoassay methods that can be inaccurate by 20–30%." Two cautions: Base and Essential both carry Marek's own warning that they do not meet the treatment requirements for Guided Optimization, so the $150 entry point is a lab purchase rather than a way into the program; and adding a 45-minute coach lab review costs $100 on the Comprehensive and Complete tiers — the cleanest number Marek publishes about its own service.

And then the gap. Marek's treatment catalogue carries no price on any of its 101 entries. Every one repeats the same line: pricing starts with the intake and the lab panel, and "if your provider determines a prescription is appropriate, medication cost is separate and varies by dose." No per-drug figure — for TRT, a peptide or a GLP-1 — is published anywhere. The honest floor for a first month is $749, and the ceiling is unknown.

What's included, and what recurs. A dedicated health coach with 1:1 protocol adjustments, monthly check-ins and provider oversight is included and specified. Standing requirements are easier to miss: "routine visits every 6 months" and "ongoing basic labs every 6 months." No insurance is accepted, and two of Marek's own documents disagree with each other — on HSA eligibility, and on whether this is a membership at all.

The pharmacy, and one badge that overreaches

Marek does something almost nobody here does: it publishes the whole dispensing chain. Its terms name seven fulfilment pharmacies with street addresses — Anazao Health, ReviveRX, Tailor Made Compounding, Empower Pharmacy, South Lake Pharmacy, Honeybee Health and Strive Pharmacy — and states a prescription "may be filled by and transferred between any of the Pharmacies."

The compounding standard in its FAQ is where it overreaches: "we only use 503A/503B FDA Approved and Audited compounding pharmacies as our fulfillment partners." Compounding pharmacies are not FDA-approved, and neither are the drugs they make: FDA's position is that it does not verify the safety, effectiveness or quality of compounded drugs before marketing, and that 503A pharmacies specifically are not subject to current good manufacturing practice requirements, unlike 503B outsourcing facilities¹. Naming the pharmacies is excellent practice. Calling them FDA-approved is not, and collapsing 503A into 503B erases the only distinction carrying regulatory weight.

The evidence behind what it sells

Marek's copy is better disciplined than most of this category, and what it gets right is worth naming first. It never claims to measure or reverse "biological age" — the phrase appears nowhere on its pages, which is rarer than it should be — and its own catalogue entry for BPC-157 says outright that there are "no completed human clinical trials; all evidence is preclinical."

The lapses are on the same shelf. The NAD+ entry describes supplementation as restoring "mitochondrial function, DNA repair, and anti-aging sirtuin activity." The 2026 PRISMA-guided systematic review of NAD+ for anti-aging and wellness screened 113 studies including 33 human intervention trials, found outcomes "heterogeneous and often null or endpoint-specific", and reported that no eligible outcomes trial has evaluated intravenous or intramuscular NAD+ for these indications at all². Sermorelin sits in the catalogue against "age-related GH decline" and "body composition optimization"; the trial that tested that molecule on that schedule gave GHRH 1-29 nightly for six weeks to eleven healthy men aged 64–76, and nocturnal growth hormone rose while IGF-1 and DEXA-measured muscle and fat did not change³. The landmark review of growth hormone in healthy older adults found small body-composition shifts, no proven functional benefit and significantly more adverse events⁴. See NAD+ for longevity, peptides for longevity, rapamycin and metformin and what's proven versus hyped.

Where it's weak, and who should skip it

Skip it if you want one number before you start — Marek gives you two of the three, and the missing one recurs. Skip it if you need insurance, an HSA claim or a diagnosis code. And skip the $150 and $250 panels if your goal is the program, because Marek says itself they do not qualify you for it. If you proceed, $749 is the floor before any medicine; get the medication figure in writing before accepting a protocol.

The verdict, against the rubric

Our rubric scores five things out of fourteen: price transparency (4), a genuine longevity line (4), clinical oversight (2), pharmacy disclosure (2) and human support (2). Marek takes the longevity line in full — TRT, twelve named peptides, NAD+, rapamycin and 130-marker panels is as deep a shelf as this board has — two for a provider exam inside the program, and two for a coach that is specified rather than implied. It takes zero on price transparency: not for hiding its labs, which it prices better than anyone here, but because no page publishes what the treatment costs, and treatment is the recurring line.

One correction we owe our own board. Marek currently scores nothing for pharmacy disclosure, on the grounds that no compounding statement could be read on a surface it controls — its site returns an empty document to automated readers. Reading its published FAQ and terms directly for this review, that is no longer right: Marek names seven dispensing pharmacies with addresses and does state a compounding standard. On our rubric that is two points it is not being credited with, making it 10 of 14 rather than 8. The letter is a B either way, and we would rather print the correction than carry a stale score.

So: the best-priced diagnostics on this board attached to the least-priced treatment. Publish a per-therapy cost band on a reachable page and Marek would be arguing for an A. The full graded field is at our provider rankings, the scoring is in how we grade, and the nearest structural comparison is our Next Health review.